EAST Search History

S29	3329	(norvir or ritonavir or "ABT-538" or "A-80538")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/08 16:02
S30	15	S28 and S29	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/08 16:02
S31	1	("5886036").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/14 10:54
S32	1	("6037157").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/14 10:54
S33	1	("6407252").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/14 10:59
S34	1	("5541206").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/14 10:59
S35	1	("5635523").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/14 11:03
S36	1	("5648497").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/14 11:05
S37	1	("6232333").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/14 11:05
S38	1	("5968987").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/23 14:23
S39	0	S38 and mono-digycer$	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 14:24
S40	0	S38 and mono-diglycer$	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 14:24

EAST Search History

S41	1	S38 and glycerid$	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 14:25
S42	1	S38 and $glyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 14:29
S43	1	("5436006").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/23 14:29
S44	0	("l6and$glyceride").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/23 14:29
S45	0	("l6and$glyceride").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/23 14:29
S46	1	S43 and $glyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 14:30
S47	1	("4722941").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/23 14:32
S48	1	S47 and $glyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 18:02
S49	825	514/310.ccls.	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 18:02
S50	142	S49 and hiv	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 18:03
S51	142	S49 and (hiv or "acquired immun$ deficien$")	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 18:04

EAST Search History

S52	117	S51 and alcohol	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 18:05
S53	130	S51 and solvent	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 18:05
S54	52	S51 and $glycerid$	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/23 18:12
S55	1	("3995069").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 08:46
S56	2225	"protease inhibit$"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 08:46
S57	117	S56 and "fatty acid$"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 08:47
S58	73	S57 and HIV	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 08:53
S59	6	S57 and ritonavir	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 09:13
S60	1	("6521651").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 10:56
S61	3482	ritonavir or norvir	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 10:57

EAST Search History

S62	7922	"proteinase inhibitor"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 10:57
S63	11244	S61 or S62	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 10:57
S64	4529	S63 and (HIV or "immun$ deficienc$")	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 10:58
S65	6599	(ethanol or butanol or propanol or ((ethyl or butyl or propyl) near5 alcohol)) and S63	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 11:06
S66	4281	S65 and ("propylene glycol" or glycol)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 11:09
S67	482	S66 and ("mono/diglycerid$" or $glyceride or campul or alkonine)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 11:11
S68	482	S67 and (PEG or polyethylene glycol)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 11:12
S69	370	S68 and (antioxid$ or ascorbic or citric)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 11:13
S70	322	S69 and (surfact$ or emulsif$ or cremofor or polysorbat$ or "castor oil")	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 11:23
S71	211	S70 and(hiv or "immun$ defienc$")	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 11:24

EAST Search History

S72	5	((OGARI) near2 (PACHECO)).INV.	US-PGPUB; USPAT	OR	ON	2007/05/24 13:33
S73	1	((ELISA) near2 (RUSOO)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/05/24 13:34
S74	10	((VALTER) near2 (RUSSO)).INV.	US-PGPUB; USPAT	OR	ON	2007/05/24 15:21
S75	5	"6923988"	US-PGPUB; USPAT	OR	ON	2007/05/24 15:21
S76	1	("6923988").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 15:23
S77	1	("6982281").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 15:27
S78	1	("6929803").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 15:29
S79	1	("6720001").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 15:31
S80	1	("7141593").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 17:04
S81	1	("4857345").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 17:05
S82	99	"oleic acid" near10 HLB	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 18:41
S83	1	("6008228").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 18:06
S84	1	("4289637").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/24 18:41
S85	1	S84 and "oleic acid"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 18:42
S86	12466	HLB and "fatty acid$"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 18:43

EAST Search History

S87	12466	HLB and "fatty acid"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 18:43
S88	1537	HLB near5 "fatty acid"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 18:43
S89	1537	HLB near5 "fatty acid"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:14
S90	3429	ritonavir	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:14
S91	2439	S90 and ethanol	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:14
S92	1583	S91 and "propylene glycol"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:15
S93	110	S92 and "PEG 400"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:15
S94	1447	S92 and ("PEG 400" or "polyethylene glycol")	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:15
S95	1256	S94 and (antioxidant or citric or ascorbic)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:16
S96	1137	S95 and (emulsion or sufactant or "castor oil" or polysorbate or cremofor)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:19

EAST Search History

S97	206	S96 and glyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:20
S98	184	S96 and $glyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:20
S99	51	S96 and monoglyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:18
S100	154	S96 and diglyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:18
S101	1056	S95 and (emulsif$ or sufactant or "castor oil" or polysorbate or cremofor)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:19
S102	172	S101 and $glyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:20
S103	185	S101 and glyceride	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/24 20:20
S104	1	("6200602").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/27 13:51
S105	1	S104 and akoline	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/27 14:07
S106	1	("6555558").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/05/27 14:28

EAST Search History

S108	33	"vacuum distilation" or "reduced pressure distilation"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/05/27 14:28
S109	331	chaturvedi.inv.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/29 11:38
S110	9	S109 and hiv	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/29 11:39
S111	468247	protease inhibitor or ritonavir	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:13
S112	149224	S111 and ethanol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:13
S113	48053	S112 and "propylene glycol"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:13
S114	7674	S113 and (monoglycer$ or diglycer$)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:14

EAST Search History

S115	2862	S114 and PEG	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:14
S116	7674	S114 and (PEG or polyethylene glycol)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:15
S117	3847	S116 and antioxid$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:16
S118	100	S117 and ritonavir	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:36
S119	3444	ritonavir	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:36
S120	2447	S119 and ethanol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:36
S121	1589	S120 and "propylene glycol"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:36

EAST Search History

S122	1450	S121 and ("PEG 400" or "polyethylene glycol")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:37
S123	204	S122 and (monoglycerid$ or diglycerid$)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:38
S124	98	S123 and antioxid$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:38
S125	63	S124 and surfact$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/03 19:38

L14 ANSWER 55 OF 59 USPATFULL on STN
ACCESSION NUMBER: 1998:24940 USPATFULL <<LOGINID::20070524>>
TITLE: Pharmaceutical composition comprising HIV protease inhibiting compounds
INVENTOR(S): Al-Razzak, Laman A., Libertyville, IL, United States
Marsh, Kennan C., Lake Forest, IL, United States
Kaul, Dilip, Waukegan, IL, United States
Manning, Lourdes P., Grayslake, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5725878		19980310
APPLICATION INFO.:	US 1995-435009		19950504 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-402690, filed on 13 Mar 1995 which is a continuation-in-part of Ser. No. US 1994-288873, filed on 15 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-267331, filed on 28 Jun 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-188511, filed on 28 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-120886, filed on 13 Sep 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Venkat, Jyothsan
LEGAL REPRESENTATIVE: Crowley, Steven R.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1,3
LINE COUNT: 2134
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM Examples of HIV protease inhibiting compounds include N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide and related compounds, disclosed in European Patent Application No. EP541168, published May 12, 1993, which is incorporated herein by reference; N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (i.e., saquinavir) and related compounds, disclosed in U.S. Pat. No. 5,196,438, issued Mar. 23, 1993, which is incorporated herein by. . . and related compounds, disclosed in European Patent Application No. EP532466, published Mar. 17, 1993, which is incorporated herein by reference; 1-Naphthoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide (i.e., 1-Naphthoxyacetyl-Mta-(2S,3S)-AHPBA-Thz-NH-tBu), 5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide (i.e., iQoa-Mta-Apns-Thz-NHtBu) and related compounds, disclosed in European Patent Application No. EP490667, published Jun. 17, 1992 and Chem. Pharm. Bull. 40 (8) 2251 (1992), which are incorporated herein by reference; [1S-[1R*(R*),2S*]}-N.sup.1 [3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-

butanediamide and related compounds, disclosed in PCT Patent Application No. WO92/08701, published May 29, 1992, which is incorporated herein by reference;. . .

SUMM . . . weight of the total solution) of water. In addition, the solution composition of the invention can comprise a pharmaceutically acceptable surfactant or a mixture of pharmaceutically acceptable surfactants. In addition, the solution composition of the invention can comprise an antioxidant (for example, ascorbic acid, BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene), vitamin E, vitamin E PEG 1000 succinate and the like) for chemical stability. Solutions encapsulated in a SEC may also comprise glycerin for physical stability.

SUMM . . . (base) or non-formulated compound II (acid addition salt), or even when compared to a mixed aqueous/organic solution (50% water, 20% ethanol, 30% propylene glycol) of compound II (methansulfonate acid addition salt).

SUMM The term "pharmaceutically acceptable organic solvent" as used herein refers to polypropylene glycol; polyethylene glycol (for example, polyethylene glycol 600, polyethylene glycol 900, polyethylene glycol 540, polyethylene glycol 1450, polyethylene glycol 6000, polyethylene glycol 8000 (all available from Union Carbide) and the like); pharmaceutically acceptable alcohols which are liquids at about room temperature, approximately 20° C., (for example, propylene glycol, ethanol, 2-(2-ethoxyethoxy)ethanol (Transcutol®, Gattefosse, Westwood, N.J. 07675), benzyl alcohol, glycerol, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400 and the like); polyoxyethylene castor oil derivatives (for example, polyoxyethyleneglyceroltriricinoleate or polyoxyl 35 castor oil (Cremophor®EL, BASF Corp.), polyoxyethyleneglycerol oxystearate (Cremophor®RH 40 (polyethyleneglycol 40 hydrogenated castor oil) or Cremophor®RH 60 (polyethyleneglycol 60 hydrogenated castor oil), BASF Corp.) and the like); saturated polyglycolized glycerides (for example, Gelucire® 35/10, Gelucire® 44/14, Gelucire® 46/07, Gelucire® 50/13 or Gelucire® 53/10 and the like, available from Gattefosse, Westwood, N.J. 07675); polyoxyethylene alkyl ethers (for example, cetomacrogol 1000 and the like); polyoxyethylene stearates (for example, PEG-6 stearate, PEG-8 stearate, polyoxyl 40 stearate NF, polyoxyethyl 50 stearate NF, PEG-12 stearate, PEG-20 stearate, PEG-100 stearate, PEG-12 distearate, PEG-32 distearate, PEG-150 distearate and the like); ethyl oleate, isopropyl palmitate, isopropyl myristate and the like; dimethyl isosorbide; N-methylpyrrolidinone; parafin; cholesterol; lecithin; suppository bases; pharmaceutically acceptable waxes (for example, carnauba wax, yellow wax, white wax, microcrystalline wax, emulsifying wax and the like); pharmaceutically acceptable silicon fluids; soribitan fatty acid esters (including sorbitan laurate, sorbitan oleate, sorbitan palmitate, sorbitan stearate and the like); pharmaceutically acceptable saturated fats or pharmaceutically acceptable saturated oils (for example, hydrogenated castor oil (glyceryl-tris-12-hydroxystearate), cetyl esters wax (a mixture of primarily C14-C18 saturated esters of C14-C18 saturated fatty acids having a melting range. . .

SUMM . . . mineral oil or a vegetable oil (for example, safflower oil, peanut oil, olive oil, fractionated coconut oil (for example, mixed triglycerides with caprylic acid and capric acid (Miglyol® 812, available from Huls AG, Witten, Germany) and the like), propyleneglycol monolaurate and the like.

ANSWER 51 OF 59 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:725436 CAPLUS <<LOGINID::20070524>>
DOCUMENT NUMBER: 133:301171
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406
CA 2366702	A1	20001012	CA 2000-2366702	20000316
EP 1165048	A1	20020102	EP 2000-916547	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated